University of Adelaide

Abbott completes enrollment in VOLT-AF IDE Study for Volt™ PFA System and launches FOCALFLEX trial for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. FDA clears Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™ for advanced cardiac mapping.

Dr. Lachlan Jolly's study at the University of Adelaide uses skin samples to resolve genetic variants of uncertain significance (VUS), activating 'silent genes' in skin fibroblasts for RNA retrieval, crucial for genetic diagnosis and access to clinical trials.

The TRIPOD+AI update provides harmonised guidance for reporting prediction model studies, superseding TRIPOD 2015, to accommodate AI and machine learning methods. The new 27-item checklist aims for complete, accurate, and transparent reporting, facilitating study appraisal and model implementation.

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.

Scientists at La Trobe University discovered WD34, an antibody-like molecule that binds to AMA1, inhibiting malaria parasite infection. WD34 targets a conserved region in AMA1, making it effective against multiple malaria species, offering hope for a broad-spectrum vaccine. Pre-clinical trials show promising results.